Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2002

View Archived Issues

Novel 5-HT1B antagonists with utility in depression identified at GSK

New adenosine A1 agonists discovered by GSK researchers

Merck scientists present novel inhibitors of factor Xa and/or factor VIIa

Sankyo describes the isolation of new antifungal agents from Phoma sp.

Series of integrin antagonists for asthma and other disorders prepared at Merck & Co.

Cholesterol-lowering efficacy of SMP-500, a novel ACAT inhibitor, in hyperlipidemic hamsters

Oregovomab enhances killer T-cell responses in apoptotic ovarian cancer cells

Pretreatment of solid tumors with NHS76/PEP2 improves efficacy of chemotherapy in mice

Emodin accelerates pancreatic regeneration in acute pancreatitis in rats

Orally active 5-HT2C receptor agonist synthesized at Vernalis as potential antiobesity agent

SLV-314: neurochemical and behavioral effects detailed at Neuroscience 2002

Binding profile of atypical antipsychotic agent SM-13496

Exanta proves superior to routinely used enoxaparin for reducing risk of VTE in major surgery

Oprelvekin reported to increase platelet counts in hepatitis C patients

Potential novel use for PPARgamma agonists discussed at AASLD meeting

Improved safety profile reported for ribavirin prodrug viramidine

Potential use of the antisense oligonucleotide ISIS-14803 in chronic HCV

Commit lozenge approved by the FDA for over-the-counter sale

Drug safety announcement regarding Refludan

Seattle Genetics releases clinical and preclinical updates

Recombinant alpha 1-antitrypsin topical gel enters clinical trials

Accelerated approval plan for KRX-101

Johnson & Johnson to acquire OraPharma

Serono and Amgen sign license agreement for multiple sclerosis product

Vertex advances Aurora kinase inhibitor into preclinical development

Immtech International completes efficacy trials of DB-289

Phase II clinical trial initiated to evaluate the efficacy of 17beta-estradiol against restenosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...